Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal

被引:7
|
作者
Saluja, Tarun [1 ]
Giri, Bishnu Rath [2 ]
Chaudhary, Shipra [4 ]
Tamrakar, Dipesh [5 ]
Kanodia, Piush [6 ]
Palkar, Sonali [7 ]
Vemula, Sridhar [1 ]
Chinaworapong, Suchada [1 ]
Kim, Bomi [1 ]
Gupta, Birendra Prasad [1 ]
Kyoung Jo, Sue [1 ]
Aspinall, Sanet [8 ]
Rai, Ganesh Kumar [3 ]
Steele, Duncan [9 ]
Kim, Jerome H. [1 ]
Wartel, T. Anh [1 ]
Sahastrabuddhe, Sushant [1 ]
机构
[1] Int Vaccine Inst, SNU Res Pk, Seoul 08826, South Korea
[2] Kanti Childrens Hosp, Pediat Hematol Oncol Unit, Kathmandu, Nepal
[3] Kanti Childrens Hosp, Kathmandu, Nepal
[4] BP Koirala Inst Hlth Sci, Dharan, Nepal
[5] Kathmandu Univ, Sch Med Sci, Dept Community Med, Dhulikhel, Nepal
[6] Nepalgunj Med Coll, Dept Pediat, Nepalganj, Nepal
[7] Bharti Hosp, Pune, Maharashtra, India
[8] Ardent Consulting Pty Ltd, Pretoria, South Africa
[9] Bill & Melinda Gates Fdn, Enter Vaccines Enter & Diarrhoeal Dis, Global Hlth, Seattle, WA USA
关键词
Capacity building; resource-limited settings; phase III; vaccine trial; clinical trial;
D O I
10.1080/21645515.2020.1855955
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Clinical trials are complicated, time-consuming and costly. From the initial screening, informed consent and recruitment of the participants' to study completion, the sponsor must undertake a wide array of complex and closely monitored operations, complying with international standards for human subject research and local requirements. Conducting these studies in an underdeveloped country, with limited resources, infrastructure, and experience with regulated clinical trials adds to this complexity. The initial site selection, set up and preparatory activities for the clinical trial are crucial to minimizing the risks to both participants and to successful completion during the subsequent study execution. In this paper, we describe the experience and lessons learned of building clinical trial site capacity in terms of infrastructure and human resource development for a Phase III vaccine clinical trial. We believe that sharing the experience of setting up a clinical trial in a resource-limited country will enable other entities contemplating clinical research in these countries, to prepare and plan ahead, to minimize the impact of barriers, and to contribute to bringing more studies to the countries where people live with the burden of vaccine-preventable, poverty-associated diseases.
引用
收藏
页码:2149 / 2157
页数:9
相关论文
共 47 条
  • [31] Community Engagement: Experience from the Thai Phase III Prime-Boost HIV Vaccine Trial, RV144
    Rerks-Ngarm, S.
    Premsri, N.
    Namwat, C.
    Pitisutthithum, P.
    Nitayaphan, S.
    Kaewkungwal, J.
    Kingko, P.
    Jirasethasiri, M.
    Paris, R.
    Chiu, J.
    Kim, J.
    Khamboonruang, C.
    Thongchareon, P.
    Kunasol, P.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (10) : A99 - A99
  • [32] A phase III clinical trial in Asia -: experience from the Asian Sildenafil (Viagra™) efficacy and safety study (ASSESS)
    Moreno, F
    Hayoun, H
    Ng, J
    ACTA PHARMACOLOGICA SINICA, 1998, 19 : 43 - 44
  • [34] Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience
    Metzger-Filho, Otto
    de Azambuja, Evandro
    Bradbury, Ian
    Saini, Kamal S.
    Bines, Jose
    Simon, Sergio D.
    Van Dooren, Veerle
    Aktan, Gursel
    Pritchard, Kathleen I.
    Wolff, Antonio C.
    Smith, Ian
    Jackisch, Christian
    Lang, Istvan
    Untch, Michael
    Boyle, Frances
    Xu, Binghe
    Baselga, Jose
    Perez, Edith A.
    Piccart-Gebhart, Martine
    ONCOLOGIST, 2013, 18 (02): : 134 - 140
  • [35] The ustekinumab safety experience in patients with moderate to severe psoriasis: Results from pooled analyses of phase II and phase III clinical trial data
    Gordon, Kenneth
    Leonardi, Craig
    Reich, Kristian
    Yeilding, Newman
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB132 - AB132
  • [36] Defining clinical trial quality from the perspective of resource-limited settings: A qualitative study based on interviews with investigators, sponsors, and monitors conducting clinical trials in sub-Saharan Africa
    De Pretto-Lazarova, Angela
    Fuchs, Claudia
    van Eeuwijk, Peter
    Burri, Christian
    PLOS NEGLECTED TROPICAL DISEASES, 2022, 16 (01):
  • [37] Impact of selected clinical pharmacy services on medication safety and prescription cost of patients attending a selected primary healthcare setting: a translational experience from a resource-limited country
    Herath, Kaumada Binoli
    Rodrigo, U. A. A.
    Senadheera, G. P. S. G.
    Samaranayaka, Shyamalee
    Samaranayake, Nithushi R.
    POSTGRADUATE MEDICAL JOURNAL, 2023, 99 (1169) : 223 - 231
  • [38] Immunogenicity Persistence of Different Immunization Regimens of Rabies Vaccine in the 10-60 Years Age Group: A Follow-Up Report Based on Phase III Clinical Trial
    Wang, Yunpeng
    Wu, Zhiang
    Li, Jia
    Cao, Shouchun
    Shi, Leitai
    Zhao, Danhua
    Mo, Zhaojun
    Liang, Haiyan
    Wu, Xiaohong
    VACCINES, 2024, 12 (11)
  • [39] Clinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis:: results from a phase III international randomized, placebo-controlled trial
    Dubertret, L.
    Sterry, W.
    Bos, J. D.
    Chimenti, S.
    Shumack, S.
    Larsen, C. G.
    Shear, N. H.
    Papp, K. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (01) : 170 - 181
  • [40] An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
    Gore, Martin
    Hackshaw, Allan
    Brady, William E.
    Penson, Richard T.
    Zaino, Richard
    McCluggage, W. Glenn
    Ganesan, Raji
    Wilkinson, Nafisa
    Perren, Timothy
    Montes, Ana
    Summers, Jeffrey
    Lord, Rosemary
    Dark, Graham
    Rustin, Gordon
    Mackean, Melanie
    Reed, Nicholas
    Kehoe, Sean
    Frumovitz, Michael
    Christensen, Helen
    Feeney, Amanda
    Ledermann, Jonathan
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 541 - 548